Akebia Therapeutics (AKBA) vs CAMP4 Therapeutics (CAMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 4.5% versus a loss of 71.4%. CAMP4 Therapeutics is the larger company by market cap ($232.2 million vs $225.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | CAMP |
|---|---|---|
| Share price | $0.8148 | $3.70 |
| Market cap | $225.79M | $232.19M |
| 1-day change | -6.71% | -3.65% |
| YTD return | -49.39% | -39.64% |
| 1-year return | -71.41% | +4.52% |
| 5-year return | -71.41% | — |
| EPS (TTM) | $-0.12 | $-2.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $7.75 |
| 52-week low | $0.814 | $2.86 |
| Distance from 52-week high | -74.54% | -52.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +381.10% | +185.68% |
| Average volume | 6.18M | 279.32K |
| Shares outstanding | 277.11M | 62.75M |
| Employees | 194 | 48 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed AKBA by 75.9 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
AKBA vs CAMP FAQ
Which is bigger, Akebia Therapeutics or CAMP4 Therapeutics?
CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $232.19M compared with $225.79M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or CAMP?
CAMP returned +4.52% over the past 12 months, compared with -71.41% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and CAMP4 Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.